Synergic Effect of Borneol and Ligustrazine on the Neuroprotection in Global Cerebral Ischemia/Reperfusion Injury: A Region-Specificity Study.
Bin YuMing RuanZhen-Nian ZhangHai-Bo ChengXiang-Chun ShenPublished in: Evidence-based complementary and alternative medicine : eCAM (2016)
The cooperation of ligustrazine (LI) and borneol was proved to be much better than each of them in treating cerebral ischemia. However, the mechanism of their synergic therapy is unclear till now. Moreover, whether their cooperation brought different degrees of protection among different brain regions was also unclear. In the present study, the effects of LI, borneol, and their mixture were observed in global cerebral ischemia-reperfusion (GCIR) injury by detecting microcirculation, expressions of caspase-3 and p53, levels of IL-1β, IL-6, and TNF-α, and contents of SOD, GSH-Px, and MDA in cortex, hippocampus, hypothalamus, and striatum, respectively. Furthermore, Nissl bodies were scored also. Monotherapy of LI or borneol showed obvious improvements in the four regions, specially in cortex and hippocampus. Interestingly, the cooperation of LI and borneol brought some new improvements, specially in hypothalamus and striatum. Thus, the synergic effect of the two drugs showed region-specificity in GCIR injury except the expressions of caspase-3 and p53.
Keyphrases
- cerebral ischemia
- subarachnoid hemorrhage
- brain injury
- blood brain barrier
- ischemia reperfusion injury
- ion batteries
- cell death
- functional connectivity
- rheumatoid arthritis
- resting state
- oxidative stress
- clinical trial
- randomized controlled trial
- cognitive impairment
- multiple sclerosis
- open label
- study protocol
- cell proliferation
- fluorescent probe
- replacement therapy
- endoplasmic reticulum stress